Neurophet, a Seoul, South Korea-based firm specializing in AI solutions for brain disorder imaging, has secured 20 billion KRW (South Korean Won).
SaaS Investors
The funding round included participation from various domestic institutional investors, such as KB Investment, Solidus Investment, Profit Asset Management, Quad Asset Management, Kolon Investment, Xolon Investment, Mirae Asset Securities, IBK, and DB Financial Investment, along with Neurophet’s Japanese business ally, Seoil E&M.
Neurophet Use of Funds
The company plans to use the funds to release a comprehensive solution for Alzheimer’s dementia next year, leveraging its AI-driven brain imaging analysis technology.
About Neurophet
Founded in 2016 by Jake Junkil Been and Donghyeon Kim, Neurophet develops medical software specialized in neurology. It has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company’s products include brain MRI imaging analysis and interpretation software "Neurophet AQUA", brain PET scan analysis (PET tracer deposition) software "Neurophet SCALE PET", brain electric and magnetic stimulation simulation software "Neurophet tES/TMS Lab", and a brain region of interest analysis research tool "Neurophet SegPlus".
Funding Details
Company: Neurophet, Inc.
Raised: KRW 20.0B
Round: Series C
Funding Month: November 2023
Lead Investors:
Additional Investors: KB Investment, Solidus Investment, Profit Asset Management, Quad Asset Management, Kolon Investment, Xolon Investment, Mirae Asset Securities, IBK, and DB Financial Investment, along with Neurophet’s Japanese business ally, Seoil E&M
Company Website: https://www.neurophet.com/
Software Category: Medical AI Software
Source: https://wowtale.net/2023/11/07/66204/